Lung Cancer Symposium

LC Virtual Symposium

Please join us for the 2022 DF/HCC Lung Cancer Program’s Annual Symposium.

Neoadjuvant Immunotherapy in the Treatment of Early-Stage Lung Cancer

8:00-8:30am	Continental Breakfast
8:30-8:40am	Introduction: Bruce Johnson, MD, Dana-Farber Cancer Institute Morning Session Chair: Lecia Sequist, MD
8:40-9:20am	Surgical Resection following Immunotherapy for Early- Stage Lung Cancer Q&A	Michael Lanuti, MD Director, Thoracic Oncology, Division of Thoracic Surgery Associate Professor Harvard Medical School Friedman-Lambert Scholar in Academic Thoracic Surgery
9:20-10:00am	Segmentectomy versus Lobectomy for Early- Stage Lung Cancer Q&A	Nasser Altorki, MD David B. Skinner, M.D. Professor of Thoracic Surgery, Cardiothoracic Surgery, Weill Cornell Medical College
10:00-11:10am	Morning Poster Session	Grand Ballroom Lobby and Hallway
11:10-11:25am	Complete anatomic segmentectomy shows improved oncologic outcomes compared to incomplete anatomic segmentectomy	Miles McAllister Research Assistant, Brigham and Women’s Hospital
11:25-11:40am	Genomic and immunophenotypic correlates of recurrence and disease-free survival after surgically-resected stage I non-small cell lung cancer (NSCLC).	Joao Alessi, MD Clinical Research Scientist II Dana-Farber Cancer Institute
11:40-12:20am	Mechanisms of Response and Resistance to Immunotherapies in Early-Stage Lung Cancer Q &A	Tina Cascone, MD, PhD Assistant Professor, Thoracic and Head and Neck Cancer, Department of Medicine MD Anderson Cancer Center
12:20-1:10pm	Lunch
	Afternoon Session Chair: Daniel Costa, MD, PhD
1:10-1:50pm	Personalizing perioperative systemic therapy in early-stage lung cancer	Mark Awad, MD, PhD Director of Clinical Research, Thoracic Oncology, Dana-Farber Cancer Institute Associate Professor of Medicine, Harvard Medical School
1:50-2:05pm	GUK1 is a novel metabolic liability in ALK+ lung cancer	Jaime Schneider, MD, PhD Assistant in Medicine, Massachusetts General Hospital Instructor in Medicine, Harvard Medical School
2:05-2:20pm	PRKRA is a preferential genetic dependency in neuroendocrine lung cancer cells	Tao Zou, MD, PhD Instructor in Medicine Dana-Farber Cancer Institute
2:20-3:00pm	Minimally Invasive Surgery for Early-Stage Lung Cancer Q&A	Paula Antonia Ugalde Figueroa, MD Associate Surgeon, Division of Thoracic Surgery Department of Surgery, Brigham and Women’s Hospital
3:00-4:10 pm	Afternoon Poster Session and Break
4:10-4:40 pm	Panel: Management of Early-Stage Lung Cancer	Scott Swanson, MD Canepari Family Distinguished Chair in Thoracic Surgery Associate Chief of Surgery, Dana-Farber Cancer Institute Professor of Surgery, Harvard Medical School
	Panel: Management of Early-Stage Lung Cancer	Michael Lanuti, MD Director, Thoracic Oncology, Division of Thoracic Surgery Associate Professor Harvard Medical School Friedman-Lambert Scholar in Academic Thoracic Surgery
	Panel: Management of Early-Stage Lung Cancer	Mark Awad, MD, PhD Director of Clinical Research, Thoracic Oncology, Dana-Farber Cancer Institute Associate Professor of Medicine, Harvard Medical School
	Panel: Management of Early-Stage Lung Cancer	Florence (Katie) Keane, MD Assistant Professor in Radiation Oncology, Harvard Medical School
	Panel: Management of Early-Stage Lung Cancer	Paula Antonia Ugalde Figueroa, MD Associate Surgeon, Division of Thoracic Surgery Department of Surgery, Brigham and Women’s Hospital
The End

POSTER DISCUSSANTS

David Christiani, MD, MPH Harvard T.H. Chan School of Public Health	Carla Kim, PhD Boston Children’s Hospital
Justin Gainor, MD, Massachusetts General Hospital	Daniel Costa, MD, PhD Dana-Farber Cancer Institute
Bruce Johnson, MD Dana-Farber Cancer Institute	Lecia Sequist, MD, MPH Massachusetts General Hospital
Chi-Fu Jeffrey Yang, MD Massachusetts General Hospital